The Motley Fool · 17 Sept 2026negative
BillionToOne's CEO sold his entire directly-held stake in the company for approximately $3 million. The transaction involved 30,331 shares executed at a weighted average price of $99.91 per share on September 14, 2026, representing 100% of the insider's directly-held equity stake plus a portion belonging to his spouse.
Why it matters — A full liquidation of the CEO's directly-held stake may signal reduced insider commitment and could be watched closely by BLLN shareholders.
PRNewsWire · 2 Sept 2026neutral
BillionToOne, Inc. (NASDAQ: BLLN) announced that its management will participate in the Wells Fargo 21st Annual Healthcare Conference, according to a press release dated September 2, 2026. The announcement from the Menlo Park, California-based molecular diagnostics company confirms the company's scheduled attendance at the conference.
Why it matters — BLLN watchers would care because the company's management participation at a major healthcare investor conference provides an opportunity for increased visibility and engagement with the investment community.
PRNewsWire · 1 Sept 2026positive
BillionToOne announced the launch of Northstar Origin, a new liquid biopsy add-on test for tissue-of-origin prediction from a single blood draw, and expanded its Northstar Select panel from 84 to 102 genes to cover genes in recent and upcoming FDA approvals.
Why it matters — The launch expands BillionToOne's liquid biopsy product offerings and panel coverage, potentially broadening its addressable market.
The Motley Fool · 28 Aug 2026neutral
BillionToOne's co-founder sold 10,000 shares at a weighted-average price of $100.00 per share on August 25, 2026, for a total of $1.0 million. Following the transaction, the insider holds a direct position of 1,000 shares, approximately 0.0022% of the company's shares outstanding.
Why it matters — Insider sell activity is often monitored by investors as a signal of management confidence in the company's outlook.
PRNewsWire · 18 Aug 2026positive
BillionToOne announced publication of a prospective, multi-site study in The Green Journal involving more than 2,200 pregnant carriers, demonstrating strong clinical performance of its cell-free DNA fetal risk assessment for recessive conditions in the general-risk population, with outcomes available for over 98% of eligible cfDNA results.
Why it matters — The study provides published clinical evidence supporting BillionToOne's cfDNA test as a primary screen for recessive conditions in general-risk pregnancies, which could strengthen the company's product positioning.
